The FDA’s joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee, and the Drug Safety and Risk Management Advisory Committee have voted 18 to 6 vote
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. It inhibits a distinct profile of angiogenic tyrosine kinase
The trial named ‘Impact of an optimized Omega 3 formulation on the biochemical and histopathological composition of atheromatous plaques in patients to undergo carotid endarectomy’, will assess the
The AGATA study is designed to evaluate the safety and efficacy of TTP399 following six months administration in subjects with type 2 diabetes mellitus on a stable dose
PKAN is a rare and life-threatening autosomal recessive neurodegenerative disorder. There are no approved treatments currently available for PKAN, which is believed to affect one to three persons
With the acceptance of PIP, the company will be able to submit a marketing authorization application (MAA) in Europe following completion of the Viaskin Peanut phase III program.
As part of the deal, Vertex will have worldwide development and commercial rights to Parion’s investigational ENaC inhibitors, including P-1037 and P-1055. Parion will receive an upfront payment
This patent is solely owned by Cynapsus and granted with claims that provide Cynapsus with protection of pharmaceutical dosage forms that combine apomorphine hydrochloride particles with an organic
About the trial The trial reached its targeted enrollment of nine patients, who are two years of age or greater but less than 12 years of age, with
HSDD is a medical condition marked by a lack of sexual thoughts and desire for sexual activity, and cannot be accounted for by another medical physical or psychiatric
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.